Neubauer, Andreas http://orcid.org/0000-0002-7606-8760
Johow, Johannes http://orcid.org/0000-0003-3494-4264
Mack, Elisabeth http://orcid.org/0000-0003-4061-494X
Burchert, Andreas
Meyn, Damaris
Kadlubiec, Andrea
Torje, Iuliu
Wulf, Hinnerk
Vogelmeier, Claus F.
Hoyer, Joachim
Skevaki, Chrysanthi http://orcid.org/0000-0001-5194-5635
Muellenbach, Ralf Michael
Keller, Christian
Schade-Brittinger, Carmen
Rolfes, Caroline
Wiesmann, Thomas
Funding for this research was provided by:
Andreas Neubauer had received institutional funding from Novartis for this study.
Johannes Johow had received institutional funding from Novartis for this study.
Carmen Schade-Brittinger had received institutional funding from Novartis for this study.
Article History
Received: 28 May 2021
Revised: 26 July 2021
Accepted: 27 July 2021
First Online: 12 August 2021
Change Date: 13 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01412-0
Competing interests
: AB receives research support for a pan-European research consortium on chronic myelogenous leukemia (EUTOS) and obtained a lecture honorarium from Novartis. CFV gave presentations at symposia and/or served on scientific advisory boards sponsored by AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Novartis, Nuvaira and MedUpdate. CS received research funding and served as a consultant for Hycor Biomedical and Thermo Fisher Scientific, from Mead Johnson Nutrition (MJN) she received research funding and served as a consultant for Bencard Allergie. AN, CSB, and JJ had received institutional funding from Novartis for this study. EM received a lecture honorarium and served on an advisory board for Roche. The remaining authors declare no competing financial interests.